National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cholic acid (Orphacol®). HTA ID: 21062

Cholic acid (Orphacol®) is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years, and adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 13/12/2021
Rapid review completed 12/01/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that cholic acid (Orphacol®) not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.